RecruitingNot Applicable

Biomarkers of Renal Cancer

Italy, Spain1,000 participantsStarted 2019-06-11

Plain-language summary

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for renal-mass patients: * Men and women over 18 years of age * Diagnosis of first episode of renal mass * Caucasian race * Signed, informed consent Exclusion Criteria renal-mass patients: * Any other concomitant cancer or history of active cancer in the last 5 years * Oncological genetic syndrome * Previous history of renal tumour * Urothelial cancer * End-stage renal disease on hemodialysis * Bilateral renal cell carcinoma Inclusion Criteria for control subjects: * Men and women over 18 years of age * Caucasian race * Living kidney donor or patient with urological functional diseases (e.g. kidney stones, benign prostate hypertrophy, etc..) * Signed, informed consent Exclusion criteria for control subjects: * History of active cancer in the last 5 years * Oncological genetic syndrome * End-stage renal disease on hemodialysis or peritoneal dialysis

What they're measuring

Screening

Timeframe: Analysis of biological samples collected before surgery

Diagnosis

Timeframe: Analysis of biological samples collected before surgery

Prognosis

Timeframe: Analysis of biological samples collected before surgery

Trial details

NCT IDNCT05785052

SponsorBiorek S.R.L.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-06

Contact for this trial

Francesco Trevisani

0226435857 francesco.trevisani@biorek.eu

View on ClinicalTrials.gov More Renal Cell Carcinoma trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.